Otofacial Neurodevelopmental Syndrome: Disease-Characteristics Report

Executive summary and evidence limits

Otofacial neurodevelopmental syndrome is an ultra-rare, newly delineated autosomal-recessive developmental disorder caused by biallelic loss-of-function variants in ZSCAN10. The disease-defining publication reported only seven affected individuals, so essentially all frequency estimates remain provisional. Its most reproducible features are global developmental delay, facial asymmetry, external-ear malformations, semicircular-canal dysplasia, and sensorineural hearing loss (SNHL), confirmed in 4/5 individuals tested. The current MONDO identifier is MONDO:0975705. Open Targets lists ZSCAN10 as the sole associated target and links the association to PMID 38386308. (OpenTargets Search: Otofacial neurodevelopmental syndrome, owrang2025neurogeneticdisorderswith pages 13-14)

The foundational primary report is Laugwitz L, Cheng F, Collins SC, et al., “ZSCAN10 deficiency causes a neurodevelopmental disorder with characteristic oto-facial malformations,” Brain. 2024;147(7):2471–2482, PMID: 38386308; PubMed: https://pubmed.ncbi.nlm.nih.gov/38386308/. A subsequent authoritative review is Owrang D, Vona B, “Neurogenetic Disorders with Hearing Loss: Mechanisms, Classifications, and Emerging Insights,” published November 2025, DOI: https://doi.org/10.1007/s11910-025-01466-y. (owrang2025neurogeneticdisorderswith pages 13-14, owrang2025neurogeneticdisorderswith pages 18-19)

Table: This table provides an evidence-bound summary of what is currently established versus unknown for otofacial neurodevelopmental syndrome, centered on the 2024 ZSCAN10 cohort report and supporting disease-resource evidence. It is useful for rapid knowledge-base population while clearly separating confirmed findings from gaps.

1. Disease information

Definition

This is a congenital/early-childhood syndromic neurodevelopmental disorder combining impaired neurodevelopment with characteristic craniofacial, external-ear, inner-ear, and auditory abnormalities. “ZSCAN10 deficiency” is the mechanistically preferable name because the demonstrated cause is biallelic ZSCAN10 loss of function. (owrang2025neurogeneticdisorderswith pages 13-14)

Identifiers and names

• MONDO: MONDO:0975705.
• Causal gene: ZSCAN10, zinc finger and SCAN domain containing 10.
• Ensembl gene: ENSG00000130182.
• Primary-literature PMID: 38386308.
• Useful synonyms: ZSCAN10-related otofacial neurodevelopmental syndrome; ZSCAN10 deficiency; neurodevelopmental disorder with characteristic oto-facial malformations.
• OMIM, Orphanet, MeSH, ICD-10, and ICD-11: no disease-specific identifiers were established in the retrieved evidence. Broad codes such as developmental disorder, congenital ear malformation, or hearing loss would be nonspecific and should not be represented as exact disease mappings. (OpenTargets Search: Otofacial neurodevelopmental syndrome, owrang2025neurogeneticdisorderswith pages 18-19)

The evidence is aggregated disease-level evidence derived from individually phenotyped patients, not EHR-derived population surveillance. The primary cohort comprised seven molecularly diagnosed individuals; Open Targets subsequently aggregated genetic evidence from EVA, UniProt literature, and Genomics England. (OpenTargets Search: Otofacial neurodevelopmental syndrome)

2. Etiology

Causal and genetic factors

The established cause is germline biallelic loss of function in ZSCAN10, consistent with autosomal-recessive inheritance. Retrieved disease-resource evidence includes frameshift and stop-gained alleles, with Open Targets/EVA confidence scores of approximately 0.90–0.92. Exact HGVS descriptions were not recoverable from the available primary-text extract and should therefore be imported directly from PMID 38386308, ClinVar, or EVA rather than inferred. (owrang2025neurogeneticdisorderswith pages 13-14, OpenTargets Search: Otofacial neurodevelopmental syndrome)

Family history, parental consanguinity, and carrier status may increase recurrence risk in the usual autosomal-recessive manner, but no founder allele, carrier frequency, modifier gene, susceptibility locus, or ancestry-specific enrichment has been established.

Environmental, infectious, and lifestyle factors

No toxins, medications, radiation, infection, maternal exposure, diet, smoking, alcohol, occupation, or other environmental cause has been linked specifically to this syndrome. No gene–environment interaction has been demonstrated. This is a monogenic developmental disorder; environmental contributors should not be asserted without new evidence.

Protective factors

No protective ZSCAN10 alleles, modifier variants, dietary factors, lifestyle exposures, or pharmacologic prophylaxis are known. Population loss-of-function constraint and allele frequencies require direct gnomAD review at variant level.

3. Phenotypes

The small denominator makes “consistent” more appropriate than a population-level percentage except where a tested denominator was reported.

These findings are directly summarized in the review as: “Biallelic ZSCAN10 loss-of-function variants were identified in seven affected individuals who consistently reported global developmental delay, facial asymmetry and malformations of the outer ear.” It further states that imaging showed semicircular-canal dysplasia and that “4/5 individuals were confirmed with SNHL.” (owrang2025neurogeneticdisorderswith pages 13-14)

No robust data are available for seizures, behavior, cognition level, speech, motor milestones, hypotonia, vestibular symptoms, growth, ophthalmology, laboratory abnormalities, or other organ involvement. Their absence from this report must not be interpreted as clinical absence.

Quality-of-life implications

No EQ-5D, SF-36, PROMIS, or syndrome-specific quality-of-life study exists in the retrieved evidence. Nevertheless, developmental delay can impair education and independent daily functioning, while SNHL can compound speech-language and social-communication disability. That functional interpretation is clinically reasonable but has not been quantified in this syndrome.

4. Genetic and molecular information

ZSCAN10 encodes a zinc-finger and SCAN-domain transcription factor. The current evidence supports biallelic germline truncating variants—frameshift and nonsense/stop-gained—as the pathogenic class. The expected consequence is loss of functional protein, rather than gain of function or dominant-negative action. Somatic causation is not implicated. (OpenTargets Search: Otofacial neurodevelopmental syndrome, owrang2025neurogeneticdisorderswith pages 13-14)

Suggested annotations include:

• Gene/protein: ZSCAN10; ENSG00000130182.
• Variant concepts: sequence variant; frameshift variant; stop-gained variant; loss-of-function variant; germline variant.
• Inheritance: autosomal recessive.
• Molecular-function GO labels: DNA-binding transcription-factor activity; sequence-specific DNA binding.
• Cellular-component GO label: nucleus.
• Biological-process GO labels: regulation of transcription by RNA polymerase II; stem-cell population maintenance; regulation of cell differentiation; embryonic development.

The retrieved evidence did not establish HGNC ID, UniProt accession, exact transcript, exact HGVS variants, gnomAD frequencies, ACMG criteria applied to each variant, penetrance, or pathogenicity of individual ClinVar records. Likewise, no modifier genes, syndrome-specific methylation signature, chromosomal rearrangement, copy-number mechanism, or repeat expansion is established.

5. Environmental information

Environmental, lifestyle, occupational, infectious, and toxicologic factors are not applicable as demonstrated primary causes. There is no evidence for infection-triggered disease or zoonotic transmission. General avoidance of ototoxic drugs is prudent for a person with SNHL, but it does not prevent the underlying genetic syndrome and is not a ZSCAN10-specific intervention.

6. Mechanism and pathophysiology

Current causal model

The best-supported chain is:

biallelic truncating ZSCAN10 variants → ZSCAN10 deficiency → disruption of transcriptional regulation during embryonic stem-cell pluripotency/lineage specification → abnormal neural and cranio-otic development → developmental delay, facial asymmetry, external-ear malformations, semicircular-canal dysplasia, and SNHL.

The first two links are genetically established; ZSCAN10’s role in embryonic stem-cell pluripotency is established gene biology; the tissue-specific developmental links are biologically plausible interpretations of the human phenotype but remain incompletely mapped. The review identifies ZSCAN10 as a transcription factor that “controls pluripotency of embryonic stem cells.” (owrang2025neurogeneticdisorderswith pages 13-14)

Upstream versus downstream

• Upstream: germline loss-of-function alleles and deficient transcription-factor activity.
• Intermediate: altered developmental transcriptional programs and cell-fate decisions; exact targets are unknown.
• Downstream: malformation of craniofacial/external-ear structures and the semicircular canals, plus neurodevelopmental and auditory dysfunction.

No disease-specific evidence currently establishes Wnt, MAPK, mTOR, PI3K–AKT, immune activation, oxidative stress, apoptosis, autophagy, fibrosis, enzyme deficiency, receptor dysfunction, ion-channel dysfunction, or a metabolic lesion. No syndrome-specific transcriptomic, proteomic, metabolomic, lipidomic, methylomic, single-cell, spatial-transcriptomic, multi-omic, CRISPR-screen, or patient-iPSC dataset was identified.

Suggested cell types—only as developmental hypotheses—include neural progenitor cells, cranial neural-crest derivatives, otic progenitors, cochlear sensory hair cells, and vestibular sensory cells. Candidate Cell Ontology labels include neural progenitor cell, neural crest cell, hair cell, and sensory neuron. These should be tagged “inferred,” not “experimentally demonstrated.”

7. Anatomical structures affected

Established or strongly indicated anatomical domains are:

• Nervous system/brain: inferred from global developmental delay; no specific cerebral lesion was recoverable.
• Craniofacial complex: facial asymmetry.
• External ear/pinna: congenital malformation.
• Inner ear/vestibular labyrinth: semicircular-canal dysplasia.
• Auditory system: SNHL, with the precise cochlear, neural, or mixed lesion not established.

Suggested UBERON labels are brain, face, external ear, inner ear, vestibular labyrinth, semicircular canal, cochlea, and auditory system. Suggested subcellular annotation is nucleus, reflecting transcription-factor localization. Laterality and degree of asymmetry were not available. (owrang2025neurogeneticdisorderswith pages 13-14)

8. Temporal development

The structural ear and facial findings imply prenatal/congenital origin; developmental delay and hearing impairment become clinically evident during infancy or childhood. The disease is expected to be lifelong. However, there is no longitudinal cohort establishing progression, developmental plateau, neurodegeneration, episodic worsening, remission, or adult natural history.

A critical practical period is early childhood, when hearing detection and language intervention may influence developmental trajectory. The expert review notes that hearing loss may occur early in neurogenetic disease and sometimes precede overt neurological findings. (owrang2025neurogeneticdisorderswith pages 13-14)

9. Inheritance and population

• Inheritance: autosomal recessive, biallelic.
• Penetrance: apparently high for the core phenotype among reported biallelic cases, but seven individuals are insufficient to estimate penetrance.
• Expressivity: likely variable, particularly for hearing loss, because only 4/5 tested individuals had confirmed SNHL; incomplete testing prevents a firm estimate.
• Anticipation: not expected and not reported.
• Germline mosaicism: not reported; a low residual recurrence risk may remain after apparently de novo findings, although de novo biallelic causation was not established here.
• Founder effects, consanguinity, carrier frequency, sex ratio, ancestry effects, and geographic clustering: unknown.
• Prevalence/incidence: unknown. Only seven cases were documented in the foundational report, which supports classification as ultra-rare but cannot yield a population prevalence. (owrang2025neurogeneticdisorderswith pages 13-14, owrang2025neurogeneticdisorderswith pages 18-19)

For confirmed carrier parents, the standard Mendelian expectation is a 25% affected, 50% carrier, and 25% unaffected/non-carrier probability in each pregnancy, assuming both parents carry pathogenic variants in the same gene.

10. Diagnostics

Recommended clinical work-up

There are no formal syndrome-specific diagnostic criteria. A reasonable approach is:

1. Document developmental history, neurologic findings, facial asymmetry, and external-ear morphology.
2. Perform age-appropriate audiology—otoacoustic emissions, auditory brainstem response in infants or uncooperative children, and behavioral pure-tone/speech audiometry when feasible.
3. Use high-resolution temporal-bone MRI or CT when inner-ear malformation is suspected; MRI documented semicircular-canal dysplasia in the reported syndrome.
4. Obtain developmental, speech-language, vestibular, and otolaryngologic assessments.
5. Confirm two pathogenic/likely pathogenic ZSCAN10 variants in trans, with parental segregation where possible. (owrang2025neurogeneticdisorderswith pages 13-14)

Genetic-testing strategy

• Preferred discovery test: trio whole-exome sequencing or whole-genome sequencing for syndromic developmental delay with hearing/ear anomalies.
• Panel testing: include ZSCAN10 on neurodevelopmental-disorder, syndromic hearing-loss, congenital ear-malformation, or intellectual-disability panels.
• Single-gene testing: suitable when the phenotype is highly characteristic or familial variants are known.
• Deletion/duplication analysis: consider if sequencing finds only one allele, although a ZSCAN10 copy-number mechanism was not established in the retrieved evidence.
• CMA: useful for the broader differential diagnosis but does not reliably detect small sequence variants.
• Karyotype/FISH, mitochondrial DNA, and repeat-expansion tests: not first-line tests for this specific molecular diagnosis.
• RNA sequencing: potentially useful to resolve splice variants, but no disease-specific diagnostic validation exists.

The 2025 review’s expert recommendation is that hearing loss in a child with developmental delay, hypotonia, or unexplained regression should prompt a neurogenetic diagnosis. (owrang2025neurogeneticdisorderswith pages 13-14)

Differential diagnosis

Consider other syndromic causes combining neurodevelopmental impairment and hearing or ear malformations, including CHARGE syndrome/CHD7 disorder, branchio-oto-renal spectrum, Kabuki syndrome, craniofacial microsomia, and other recently defined neurogenetic hearing-loss disorders. Distinguishing features for ZSCAN10 deficiency are recessive inheritance and the combination of facial asymmetry, external-ear malformation, semicircular-canal dysplasia, and developmental delay. Because the cohort is very small, this gestalt is supportive rather than diagnostic.

11. Outcome and prognosis

Survival, mortality, life expectancy, adult independence, seizure risk, and long-term neurologic progression have not been quantified. No disease-specific prognostic biomarkers or prediction model exists. Likely morbidity arises from developmental disability and hearing impairment. Recovery of the congenital syndrome is not expected, although hearing, communication, education, and adaptive function may improve with early supportive intervention. No formal quality-of-life or disability-scale data are available.

12. Treatment

There is no approved disease-modifying therapy, genotype-specific drug, gene therapy, RNA therapy, cell therapy, immunotherapy, or registered disease-specific interventional trial in the retrieved evidence.

Management should therefore be individualized and multidisciplinary:

• early-developmental services and special education;
• speech-language therapy, including augmentative and alternative communication when required;
• audiology and otolaryngology follow-up;
• hearing aids where residual hearing permits;
• cochlear-implant evaluation for severe/profound SNHL, with anatomy assessed because semicircular-canal dysplasia is present;
• occupational and physical therapy according to functional deficits;
• vestibular assessment and balance therapy if symptomatic;
• clinical-genetics follow-up and family counseling.

These are extrapolated standards for developmental disability and pediatric SNHL, not interventions tested specifically in ZSCAN10 deficiency. Suitable NCIT concept labels include Genetic Counseling, Audiologic Examination, Hearing Aid, Cochlear Implantation, Speech and Language Therapy, Occupational Therapy, and Physical Therapy.

No response rates, adverse-event series, pharmacogenomic recommendations, combination algorithms, or experimental NCT identifiers exist for this syndrome.

13. Prevention

Primary prevention through lifestyle modification, vaccination, or avoidance of an exposure is not available. Reproductive prevention options after familial variants are known include carrier testing of relatives, prenatal diagnosis, and preimplantation genetic testing for monogenic disease. Secondary prevention consists of early molecular diagnosis, audiologic surveillance, and prompt developmental/hearing intervention. Tertiary prevention aims to limit communication, educational, balance, and functional complications. Genetic counseling should explain autosomal-recessive recurrence and available reproductive choices.

Population newborn genomic or carrier screening is not currently supported by prevalence, natural-history, or implementation evidence. Standard newborn hearing screening may detect hearing impairment but is neither sensitive nor specific for ZSCAN10 deficiency.

14. Other species and natural disease

No naturally occurring ZSCAN10-related otofacial neurodevelopmental syndrome was identified in companion animals, livestock, or wildlife. No breed association, OMIA entry, veterinary burden, cross-species transmission, or zoonotic potential was established. Orthologues likely exist in standard vertebrate models, but NCBI Gene and taxon identifiers should be verified directly before database import.

15. Model organisms and experimental systems

The retrieved literature supports a role for ZSCAN10 in embryonic stem-cell pluripotency and transcriptional regulation, but it did not establish a syndrome-specific knockout or knock-in animal model that recapitulates the human neurodevelopmental, external-ear, semicircular-canal, and hearing phenotypes. Accordingly, no model can yet be rated for phenotypic fidelity. (owrang2025neurogeneticdisorderswith pages 13-14)

High-priority future models are:

• CRISPR ZSCAN10-null human iPSCs differentiated toward neural-crest, neural, and otic lineages;
• patient-derived iPSCs with isogenic correction;
• zebrafish or mouse knockout/knock-in models assessed for craniofacial symmetry, ear morphology, vestibular function, auditory thresholds, and neurobehavior;
• rescue experiments restoring wild-type ZSCAN10 to establish causal reversibility;
• single-cell RNA/ATAC sequencing during otic and neural differentiation to identify downstream transcriptional targets.

These are proposed research applications, not currently validated implementations.

Overall assessment

The syndrome–gene relationship is supported by a coherent 2024 human cohort, recessive loss-of-function genetics, and a biologically plausible role for ZSCAN10 in developmental transcription. Its defining clinical signal is the conjunction of developmental delay with characteristic otofacial and inner-ear abnormalities. Nevertheless, the evidence base remains at the initial disease-description stage: seven cases, incomplete hearing testing, no prevalence estimate, no longitudinal natural history, no disease-specific therapy, and no validated model or molecular biomarker. The immediate real-world application is therefore improved genomic diagnosis and early audiologic/developmental management—not molecularly targeted treatment. (owrang2025neurogeneticdisorderswith pages 13-14, OpenTargets Search: Otofacial neurodevelopmental syndrome)

References

1. (OpenTargets Search: Otofacial neurodevelopmental syndrome): Open Targets Query (Otofacial neurodevelopmental syndrome, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (owrang2025neurogeneticdisorderswith pages 13-14): Daniel Owrang and Barbara Vona. Neurogenetic disorders with hearing loss: mechanisms, classifications, and emerging insights. Current Neurology and Neuroscience Reports, Nov 2025. URL: https://doi.org/10.1007/s11910-025-01466-y, doi:10.1007/s11910-025-01466-y. This article has 2 citations and is from a domain leading peer-reviewed journal.

3. (owrang2025neurogeneticdisorderswith pages 18-19): Daniel Owrang and Barbara Vona. Neurogenetic disorders with hearing loss: mechanisms, classifications, and emerging insights. Current Neurology and Neuroscience Reports, Nov 2025. URL: https://doi.org/10.1007/s11910-025-01466-y, doi:10.1007/s11910-025-01466-y. This article has 2 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00